Abstract

The consumption of seafood and the use of fish oil for the production of nutraceuticals and fish feed have increased over the past decades due the high content of long-chain polyunsaturated omega-3 fatty acids. This increase has put pressure on the sustainability of fisheries. One way to overcome the limited supply of fish oil is to harvest lower in the marine food web. Calanus finmarchicus, feeding on phytoplankton, is a small copepod constituting a considerable biomass in the North Atlantic and is a novel source of omega-3 fatty acids. The oil is, however, different from other commercial marine oils in terms of chemistry and, possibly, bioactivity since it contains wax esters. Wax esters are fatty acids that are esterified with alcohols. In addition to the long-chain polyunsaturated omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the oil is also rich in stearidonic acid (SDA), long-chain monounsaturated fatty acids, and the long-chain fatty alcohols eicosenol and docosenol. Recent animal studies have indicated anti-inflammatory and anti-obesogenic actions of this copepod oil beyond that provided by EPA and DHA. This review will discuss potential mechanisms behind these beneficial effects of the oil, focusing on the impact of the various components of the oil. The health effects of EPA and DHA are well recognized, whereas long-chain monounsaturated fatty acids and long-chain fatty alcohols have to a large degree been overlooked in relation to human health. Recently, however the fatty alcohols have received interest as potential targets for improved health via conversion to their corresponding fatty acids. Together, the different lipid components of the oil from C. finmarchicus may have potential as nutraceuticals for reducing obesity and obesity-related metabolic disorders.

Highlights

  • It is widely accepted that the omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFA) eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), present in seafood, have health benefits in several human diseases and conditions, such as cardiovascular and inflammatory diseases

  • Zooplankton and small crustaceans like krill that feed on phytoplankton, the producers of the n-3 LC-PUFA, are to some degree being utilized for production of marine oil nutraceuticals

  • The oil from Calanus finmarchicus is a marine oil with a unique chemistry

Read more

Summary

Introduction

It is widely accepted that the omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFA) eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), present in seafood, have health benefits in several human diseases and conditions, such as cardiovascular and inflammatory diseases. They play a critical role in neural development (Campoy et al, 2012; Delgado-Lista et al, 2012; Calder, 2015). The use of fish oil in aquaculture feed and as a nutraceutical for direct human consumption has increased over the past decades (Tocher, 2015). Zooplankton and small crustaceans like krill that feed on phytoplankton, the producers of the n-3 LC-PUFA, are to some degree being utilized for production of marine oil nutraceuticals

Objectives
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call